A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Trial status:Recruiting
Study Identifier:
DB-1303-O-1001
ClinicalTrials.gov Identifier:
NCT05150691
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
DualityBio Inc.
Recruiting

Trial details

Medical Condition
  • Solid Tumors
    • Study Drug
  • Biological: DB-1303/BNT323
  • Drug: Pertuzumab Injection
  • Drug: Ritonavir
    • See more
  • Drug: Itraconazole
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+
    Estimated Trial Date
    Jan 2022 - Apr 2026

    Protocol summary

    This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

    Trial locations

    Location
    Status
    Location
    TOI Clinical Research
    Cerritos, California, United States, 90703
    Status
    Recruiting
    Location
    California Research Institute
    Los Angeles, California, United States, 90027
    Status
    Recruiting
    Location
    Washington Cancer Institute at MedStar Washington Hospital Center
    Washington, District of Columbia, United States, 20010
    Status
    Recruiting
    Location
    Advanced Research LLC
    Coral Springs, Florida, United States, 33065
    Status
    Recruiting
    Location
    The Oncology Institute of Hope and Innovation
    Lakeland, Florida, United States, 33812
    Status
    Recruiting
    Location
    D&H Cancer Research Center LLC
    Margate, Florida, United States, 33063
    Status
    Recruiting